arterial hypertrophy

Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat.

PDE5-IN-1 (compound 2) is a PDE5 inhibitor with an IC50 of 5.6 nM and demonstrates oral bioavailability. It forms a hydrogen bond interaction with the Q817 residue and an aromatic π-π stacking interaction with the F820 residue in the PDE5 catalytic domain. Additionally, PDE5-IN-1 exhibits anti-myocardial hypertrophy and vasodilation effects, reducing mean pulmonary arterial pressure and right ventricular hypertrophy index. This compound is useful in pulmonary hypertension research.

Chlorthalidone impurity G is a potential impurity found in commercial preparations of chlorthalidone that has moderate antihypertensive effects. Chlorthalidone is a thiazide-like diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, which prevents reabsorption of sodium and chloride leading to a reduction in plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including the isoforms CAVB, VII, IX, XII, and XIII (Kis = 2.8-23 nM) and, to a lesser extent, CAI, CAII, IV, VA, and VI (Kis = 138-1,347 nM), which may mediate its sustained vasodilatory activity. Dietary administration of chlorthalidone (8 mg per animal per day) reduces arterial hypertension and prevents or reduces ventricular hypertrophy induced by deoxycorticosterone acetate (DOCA) in salt-hypertensive rats. Formulations containing chlorthalidone have been used alone or in combination with other antihypertensive agents to lower arterial blood pressure and as adjuvants to address edema caused by cardiac or renal disorders.

Getagozumab is a humanized IgG4-kappa monoclonal antibody that specifically targets endothelin receptor type A (EDNRA) with potent antagonistic activity. Getagozumab significantly lowered pulmonary arterial pressure in both hypoxia-induced and monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) monkey models and further attenuated the associated pulmonary arterial and right ventricular hypertrophy.